Where do Sutro Biopharma's ratios come from?

Every ratio is computed from Sutro Biopharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Sutro Biopharma STRO Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Profitability
Operating margin	-120%—	-154.5%—	-175.7%—	——	——
Net margin	-154.2%—	-186.5%—	-205.2%—	——	——
EBITDA margin	-113.3%—	-147.4%—	-168.5%—	——	——
Free cash flow margin	-152.2%—	-172.9%—	-210.7%—	——	——
Returns
Return on assets	-54.5%—	-68.1%—	-65.5%—	——	——
Efficiency
Asset turnover	0.4×+0.2×	0.4×+0.2×	0.3×0.0×	0.3×-0.1×	0.2×-0.2×
Liquidity
Current ratio	3.1×+1.0×	2×-0.6×	2.5×-0.6×	3.1×-0.3×	2.2×-2.3×
Quick ratio	3.1×+1.0×	2×-0.6×	2.5×-0.6×	3.1×-0.3×	2.2×-2.3×
Cash ratio	1×+0.2×	0.8×-0.7×	0.9×-0.4×	0.9×+0.2×	0.8×0.0×
Leverage
Debt-to-assets	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Per Share
Book value per share	-$5.11-65.7%	-$15.59-370%	-$1.03-176%	-$0.38-120%	-$3.09-293%
Valuation
Market capitalization	$489.66M+624%	$98.57M-35.0%	$73.62M-73.8%	$69.46M-70.8%	$54.5M-84.3%
Enterprise value	$429.61M-2,600%	$56.11M+464%	$25.35M-80.7%	$25.03M-85.6%	-$30.33M-110%
Price / sales	4.9×+3.9×	1×-1.5×	0.7×-1.0×	0.7×-0.7×	0.8×-1.4×
EV / sales	4.3×+4.6×	0.5×+0.8×	0.2×-0.6×	0.2×-0.8×	-0.5×-2.5×
Free cash flow yield	-31%+272pp	-179.8%—	-302.4%—	——	——
Earnings yield	-31.4%+331pp	-193.9%—	-294.4%—	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Sutro Biopharma.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

Where do Sutro Biopharma's ratios come from?: Every ratio is computed from Sutro Biopharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.